OBJECTIVES: To assess the cost-effectiveness of sucroferric oxyhydroxide compared with sevelamer carbonate, sevelamer hydrochloride, calcium carbonate, calcium acetate, calcium acetate+magnesium carbonate in patients with hyperphosphatemia with chronic kidney disease in Russia for 1-year period. METHODS: A decision tree was used to simulate the effects of medicinal drugs. The data on drugs efficacy (measured as survival for 1 year) was obtained from available clinical trials. The following costs were taken into account: the cost of drug therapy of hyperphosphatemia, cost for treatment of cardiovascular complications of chronic kidney disease, cost of drug therapy of anemia and secondary hyperparathyroidism in chronic kidney disease, costs for treatment of chronic kidney disease. As a result cost-effectiveness ratio (CER) of phosphate binders was calculated. RESULTS: Therapy with sucroferric oxyhydroxide and sevelamer carbonate and hydrochloride leads to the equal 1-year survival as 88% (according to Florian S. Gutzwiller,2015), therapy with calcium carbonate, calcium acetate and calcium acetate+magnesium carbonate results in 66 % survival according to the meta-analysis by Jamal S.A. The calculated CER per 1 % of survival per year was lowest for sucroferric oxyhydroxide – 1 663 679 RUB/25173 $ in comparison with sevelamer carbonate - 1 723 277 RUB/26098 $, sevelamer hydrochloride - 1 723 299 RUB/26098 $, calcium carbonate – 2 381 086 RUB/36061 $, calcium acetate – 2 286 086 RUB/34 622 $, calcium acetate+magnesium carbonate – 2 416 638 RUB/36 599 $. Current rate taken as for 15.06.2016 is 1$ = 66,09 RUB. CONCLUSIONS: The choice of sucroferric oxyhydroxide instead of other phosphate binders in Russian healthcare conditions is considered cost-effective in patients with hyperphosphatemia with chronic kidney disease.